|
Pronunciation |
|
(ep
i NEF rin, ra SEE
mik) |
|
|
U.S. Brand
Names |
|
AsthmaNefrin®; microNefrin®;
Nephron®; S-2®; Vaponefrin® |
|
|
Generic
Available |
|
Yes |
|
|
Pharmacological Index |
|
Alpha/Beta Agonist; Vasoconstrictor |
|
|
Adverse
Reactions |
|
No data reported |
|
|
Drug
Interactions |
|
No data reported |
|
|
Pharmacodynamics/Kinetics |
|
Absorption: Not absorbed orally
Onset of bronchodilation:
Subcutaneous: Within 5-10 minutes
Inhalation: Within 1 minute |
|
|
Dietary
Considerations |
|
No data reported |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Dosage Forms |
|
Solution, inhalation:
Vaponefrin®: Racepinephrine 2% [epinephrine base 1%]
(15 mL, 30 mL) |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|